AstraZeneca has terminated all development of vemircopan, the oral factor D inhibitor it acquired through the deal for ...

It took one month for Johnson & Johnson to secure its $14 billion acquisition of Intra-Cellular Therapies, according to new ...

After promoting its oncology officer Chris Boshoff to chief scientific officer last fall, Pfizer has found his successor.

Per­son­i­fy Health, which sells health­care spend­ing man­age­ment ser­vices to em­ploy­ers, has reached more than half a ...

AstraZeneca on Thursday provided insight on an ongoing China probe into the company concerning alleged illegal drug imports, ...

Eli Lilly reports 45% Q4 revenue jump to $13.53B, missing projections. Company maintains 2025 revenue outlook of $58-61B amid competition with Novo Nordisk in obesity market.

Bristol Myers Squibb announces $2B in new cost cuts over 3 years, including workforce reductions, following $1.5B cuts in ...

Many Americans have flocked to cheaper, compounded versions of GLP-1 weight loss drugs in lieu of brand-name treatments. That ...

All nine late-stage kidney cancer patients in a Phase 1 trial of a personalized vaccine remained cancer-free after more than three years of receiving treatment, researchers wrote in a Nature paper ...

Revance Therapeutics accepts Crown Laboratories' $3.65/share acquisition offer over rival bid from Teoxane, ending battle for ...

Bristol Myers Squibb cuts 67 jobs in Lawrence Township, NJ, while Kyowa Kirin lays off 52 employees at Princeton facility, per NJ WARN notices.

EyePoint's Duravyu meets primary endpoint in Phase 2 DME trial, showing potential to compete with Regeneron's Eylea and Roche ...